

March 24, 2026  
Fuji Pharma Co., Ltd.

## **Fuji Pharma and Gedeon Richter Conclude Agreement for Joint Development Projects in Women's Health**

Fuji Pharma Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; hereinafter "Fuji Pharma") announces that, in relation to the strategic collaboration with Gedeon Richter Plc. (Headquarters: Hungary; hereinafter "Richter") disclosed on February 3, 2026, the two companies have entered into and signed an agreement regarding the joint development of multiple product candidates in the field of women's health.

The first project involves the development of FMC2, a first-in-class antibody discovered by FimmCyte AG as a potential treatment for endometriosis. Endometriosis affects a large number of women worldwide; however, there is currently no curative therapy for this disease. FMC2 is expected to have the potential to exert disease-modifying effects in endometriosis and may represent a meaningful advance in the treatment of endometriosis.

The second project relates to a women's health drug discovery portfolio acquired by Richter from U.S.-based Celmatix Inc.

The portfolio acquired by Richter from Celmatix and agreed upon by Fuji Pharma includes a first-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist with the potential to transform fertility care by enabling more patient-friendly ovarian stimulation. The portfolio also features a novel Jun N-terminal kinase (JNK) inhibitor, which represents a potential non-hormonal immunotherapy approach for endometriosis aimed at addressing both pain and inflammation. In addition, the acquisition comprises early-stage therapeutic antibodies targeting anti-Müllerian hormone (AMH), including both agonists and antagonists, with the potential to provide unprecedented control over ovarian folliculogenesis.

Investment and innovation in women's healthcare remain insufficient. Globally, research and development in this area is estimated to account for less than five percent of overall pharmaceutical R&D, resulting in limited treatment options for the future, and at the same time creating opportunities for innovative companies willing to invest. Against this backdrop, Richter and Fuji Pharma have signed a Business Collaboration Agreement that will strengthen joint efforts in business development and R&D within gynecology, a strategic priority area for both parties.

Based on this agreement, Fuji Pharma will hold the rights to develop, manufacture, and commercialize the product candidates subject to this agreement in Japan, the ASEAN countries, and South Korea, while it will contribute to the R&D expenses. This initiative further deepens Fuji Pharma's expertise in the women's health field and enhances the execution of the Company's strategy of "continuously creating new value in women's health."

Details of each development project will be announced at an appropriate time, taking into consideration future development progress

■ About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation.

For more information, please visit [www.gedeonrichter.com](http://www.gedeonrichter.com)

■ About FimmCyte AG

FimmCyte is a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases. Founded in 2022 as a spin-off from the University of Zürich and University Hospital Zürich, FimmCyte is advancing a pipeline designed to target key drivers of disease and deliver lasting clinical impact. By moving beyond symptom management, FimmCyte aims to improve the daily life of people living with chronic, debilitating conditions.

For more information, please visit [www.fimmcyte.com](http://www.fimmcyte.com)

■ About Celmatix Inc.

Celmatix is a preclinical-stage women's health biotech focused on advancing groundbreaking therapeutics. Celmatix was founded in 2009 with the conviction that female biology is distinct and deserves to be studied, understood, and treated with the same scientific rigor applied to every other area of medicine. With its pipeline of innovative drug programs, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in women's health.

For more information, visit [www.celmatix.com](http://www.celmatix.com)

**For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsks@fujipharma.jp](mailto:fsks@fujipharma.jp)